This is caused by the high immunogenicity and extensive T-cell infiltration of dMMR/MSI-H tumor tissues, which increases their sensitivity to programmed cell death protein 1 (PD-1)/ programmed cell death protein ligand 1 (PDL-1) inhibitor therapy with a better clinical response [93, 94]. Here, PDCD1 is linked to neoplasm.